Scarica l'app Stockscreener
85.33
0.32%
-0.27
Dopo l'orario di chiusura:
85.33
Precedente Chiudi:
$85.60
Aprire:
$85.89
Volume 24 ore:
747.08K
Relative Volume:
0.82
Capitalizzazione di mercato:
$4.89B
Reddito:
$360.35M
Utile/perdita netta:
$-149.57M
Rapporto P/E:
-28.83
EPS:
-2.96
Flusso di cassa netto:
$-81.27M
1 W Prestazione:
-1.94%
1M Prestazione:
+3.62%
6M Prestazione:
-3.91%
1 anno Prestazione:
-33.44%
Intervallo 1D:
$84.54
$87.48
Intervallo di 1 settimana:
$82.19
$87.48
Portata 52W:
$77.10
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Nome
Glaukos Corporation
Settore
Industria
Telefono
949-367-9600
Indirizzo
1 GLAUKOS WAY, ALISO VIEJO, CA
Confronta GKOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
85.33 | 4.89B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
127.63 | 231.95B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
97.78 | 142.60B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.25 | 141.45B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.04 | 123.83B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.65 | 43.07B | 5.69B | 1.41B | 577.90M | 6.9828 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-01 | Iniziato | Goldman | Buy |
| 2025-05-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-12-06 | Iniziato | UBS | Buy |
| 2024-12-02 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Iniziato | Truist | Buy |
| 2023-11-08 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-10-14 | Ripresa | Stephens | Overweight |
| 2022-10-04 | Iniziato | Needham | Buy |
| 2022-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2022-02-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2021-11-03 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-12-09 | Iniziato | Oppenheimer | Perform |
| 2020-11-17 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Iniziato | Jefferies | Hold |
| 2020-03-05 | Iniziato | Citigroup | Sell |
| 2020-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2019-12-12 | Downgrade | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Iniziato | BTIG Research | Neutral |
| 2018-08-30 | Iniziato | Berenberg | Hold |
| 2018-08-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Reiterato | Stifel | Hold |
| 2018-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Downgrade | Stifel | Buy → Hold |
| 2018-03-01 | Reiterato | Cantor Fitzgerald | Buy |
| 2017-03-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Aggiornamento | Stifel | Hold → Buy |
| 2016-10-27 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Glaukos Corporation Borsa (GKOS) Ultime notizie
Combining machine learning predictions for Glaukos CorporationJuly 2025 Decliners & Weekly Market Pulse Updates - newser.com
Does Glaukos Corporation qualify in momentum factor screeningJuly 2025 Gainers & Comprehensive Market Scan Reports - newser.com
Can Glaukos Corporation hit a new high this month2025 Stock Rankings & Expert Curated Trade Ideas - newser.com
Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting - BioSpace
Earnings call transcript: Glaukos Q2 2025 reports record sales, stock rises - Investing.com
What to do if you’re stuck in Glaukos CorporationPortfolio Return Report & Low Volatility Stock Suggestions - newser.com
Glaukos Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
How cyclical is Glaukos Corporation (6GJ) stock compared to rivalsJuly 2025 Closing Moves & Technical Analysis for Trade Confirmation - newser.com
Will Glaukos Corporation stock outperform energy sector in 2025July 2025 Chart Watch & Low Drawdown Momentum Trade Ideas - newser.com
How to build a custom watchlist for Glaukos Corporation2025 Market Outlook & Real-Time Buy Zone Alerts - newser.com
What analysts say about Glaukos Corporation stockStock Price Divergence & Small Budget Trading Plans - earlytimes.in
How strong dollar benefits Glaukos Corporation (6GJ) stock2025 Key Lessons & Free Reliable Trade Execution Plans - newser.com
Will Glaukos Corporation stock attract long term capital inflowsQuarterly Profit Summary & Detailed Earnings Play Strategies - newser.com
Glaukos (GKOS) Analyst Rating Update: BTIG Lowers Price Target | - GuruFocus
Is Glaukos Corporation stock dividend yield sustainable2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Glaukos Corporation (GKOS) Stock Report: Analyzing a 43.53% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
How to read the order book for Glaukos CorporationWeekly Profit Summary & Community Verified Watchlist Alerts - newser.com
Using Python tools to backtest Glaukos Corporation strategiesJuly 2025 WrapUp & Free Daily Entry Point Trade Alerts - newser.com
Glaukos gains as Goldman Sachs initiates at Buy on valuation - MSN
InvestingPro’s January Glaukos warning preceded 47% stock drop By Investing.com - Investing.com Australia
Glaukos Corporation stock trend outlook and recovery pathQuarterly Trade Review & Reliable Entry Point Alerts - newser.com
How hedge fund analytics apply to Glaukos Corporation stockPrice Action & Advanced Swing Trade Entry Plans - newser.com
Glaukos Corporation (NYSE:GKOS) Shares Could Be 46% Below Their Intrinsic Value Estimate - 富途牛牛
Analyzing net buyer seller activity in Glaukos Corporation2025 Breakouts & Breakdowns & Trade Opportunity Analysis Reports - newser.com
Glaukos' (GKOS) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Glaukos breaks ground on high-tech facility in Alabama, eyes 150 jobs - Alabama News Center
Stifel maintains Buy rating on Glaukos stock ahead of Epioxa PDUFA date - Investing.com Nigeria
Stifel maintains Buy rating on Glaukos stock ahead of Epioxa PDUFA date By Investing.com - Investing.com South Africa
Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 - The Globe and Mail
Glaukos breaks ground on high-tech facility in Huntsville, eyes 150 jobs - Alabama Department of Commerce
Citigroup Issues Pessimistic Forecast for Glaukos (NYSE:GKOS) Stock Price - MarketBeat
GKOS: Citigroup Lowers Price Target, Maintains Buy Rating | GKOS Stock News - GuruFocus
Volume spikes in Glaukos Corporation stock – what they meanQuarterly Portfolio Summary & High Accuracy Buy Signal Tips - newser.com
Glaukos Corporation (GKOS) Investor Outlook: Exploring a 38% Potential Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
Is Glaukos Corporation stock bottoming outJuly 2025 Analyst Calls & Short-Term High Return Ideas - newser.com
Glaukos (GKOS): Valuation Spotlight as Goldman Sachs Highlights Pharma Growth Pivot and Innovative Pipeline - simplywall.st
Will Glaukos Corporation benefit from macro trends2025 Support & Resistance & High Yield Stock Recommendations - newser.com
Quantitative breakdown of Glaukos Corporation recent moveMarket Activity Recap & Real-Time Volume Analysis - newser.com
Glaukos Corporation Azioni (GKOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):